Accuride (ACW) –
-
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
-
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
-
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
-
Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
-
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
-
Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update
-
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention
-
Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference
-
FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial
-
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
-
Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients
-
Elliott Management Nominates Independent, Highly Qualified Trustee Candidates to the Board of Public Storage
-
Cognitive Improvement Demonstrated With Xanamem™: Actinogen Medical
-
Final Patient Enrolled in Landmark Alzheimer’s Treatment Trial Targeting Stress Hormone Cortisol
-
Form 15-12G ACCURIDE CORP
-
Form SC 13D/A ACCURIDE CORP Filed by: Cetus Capital, LLC
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: Littlejohn Fund IV, L.P.
-
Form 4 SG Distressed Fund, LP For: Nov 18 Filed by: Littlejohn Opportunities GP LLC
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: Hazlett Scott D.
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: Martin Stephen Albert
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: RULSEH JAMES R
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: BUSSE KEITH E
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: Blair Mary Elizabeth
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: HAJOST MICHAEL A
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: Risch Gregory Alan
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: KLING LEWIS M
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: RISNER JOHN W
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: ADAMS ROBIN J
-
Form 4 ACCURIDE CORP For: Nov 18 Filed by: DAUCH RICHARD F
-
Form S-8 POS ACCURIDE CORP
-
Form S-8 POS ACCURIDE CORP
-
Form 25-NSE ACCURIDE CORP Filed by: NEW YORK STOCK EXCHANGE LLC
-
Form 8-K ACCURIDE CORP For: Nov 17
-
Crestview Partners Completes Accuride (ACW) Acquisition
-
Accuride Corporation Announces Completion of Acquisition by Crestview Partners
-
Accuride Corporation Announces Expiration and Results of Cash Tender Offer for Its 9.5% First Priority Senior Secured Notes Due 2018
-
Form 8-K ACCURIDE CORP For: Nov 15
-
Accuride Shareholders Approve Transaction with Crestview
-
Form 8-K ACCURIDE CORP For: Nov 08
-
Form DEFA14A ACCURIDE CORP
-
Form 8-K ACCURIDE CORP For: Nov 04
-
Form DEFA14A ACCURIDE CORP
-
Accuride Corporation Sends Letter to Shareholders and Recommends a Vote “FOR” the Crestview Transaction on the WHITE Proxy Card Today
-
Form 8-K ACCURIDE CORP For: Nov 03
-
Form DEFA14A ACCURIDE CORP
-
Form 8-K ACCURIDE CORP For: Nov 02
-
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Accuride Shareholders Vote “FOR” Proposed Crestview Transaction
-
Form 8-K ACCURIDE CORP For: Nov 01
-
Accuride Corporation Announces Early Results of Tender Offer and Consent Solicitation for Cash for Any and All of Its 9.5% First Priority Senior Secured Notes Due 2018
-
Form 10-Q ACCURIDE CORP For: Sep 30
Back to ACW Stock Lookup
